Guidance for the use and prescribing of PCSK9 inhibitors

Primary care guidance for the prescribing and supply of Inclisiran

Inclisiran for the treatment of familial or non-familial hyperlipidaemia in secondary prevention of CVD

Summary of national guidance for lipid management for primary and secondary prevention of cardiovascular disease

NHS South West Strategic Clinical Network - Top tips for managing AF

Clinical guidelines for Secondary Prevention after Stroke or TIA

Inhixa (enoxaparin biosimilar) Information sheet

1. Please specify the brand when prescribing a modified-release preparation of nifedipine, diltiazem (excluding 60 mg tablet) or verapamil to ensure that the patient receives the same modified-release preparation. Where a patient already receives a modified-release preparation, the existing brand should be prescribed.

2. Co-prescribing of diltiazem and a  beta-blocker should be undertaken with caution and initiated only under hospital supervision.

3. Verapamil should NOT be used with a beta-blocker.

4. The use of calcium channel blockers with a direct effect on cardiac contractility ie verapamil or diltiazem should be specifically avoided in heart failure.

1. Nifedipine modified release capsules (eg Coracten XL^®) are used in hospital for the management of hypertensive emergency.

2. Nifedipine short acting capsules are occasionally used in primary care for Raynaud's but are NOT  recommended for angina or long term management of hypertension.